At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
ferric citratedrug
Likely dose
ferric citrate 210 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-Week Feasibility Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)
In Brief
An observational study evaluating ferric citrate for Hyperphosphatemia and 2 related conditions. Completed, enrolled 22 participants across 3 sites.
Detailed Summary
The objective of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a dietary phosphate binder in controlling and managing serum phosphorus levels in patients with end-stage renal disease (ESRD).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesIsrael
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartJan 2010
Primary CompletionMay 2010
TodayJul 2026
First PostedAug 28, 2009
Enrollment StartJan 1, 2010
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.8 years ago
Interventions
ferric citratedrug
KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate